Mm II Assignment

AMARJIT SINGH ID No. MHS1007002

INTRODUCTION

• Multinational Pharmaceuticals Company.

• World’s 4th Largest.

• Founded in 20 August 2004.

• Head Quarter- Paris, France.

INTRODUCTION

• CE0 - Chris Viehbacher

• CHAIRMAN - Jean Francois Dehecq

• REVENUE - € 29.31 billion (2009)

• PROFIT - € 5.265 billion (2009)

INTRODUCTION

• It is a Member of- European Federation of Pharmaceutical Industries & Associations (EFPIA).

GENERAL INFORMATION

• Revenue - €29.31billion (2009)

• Operating Income - €6.366billion (2009)

• Profit - €5.265billion (2009)

• Market Share - 4.3%

• Employees - 104,870 (2009)

WHAT BUSINESS ARE THEY IN

• Manufacturing & Marketing of Pharmaceutical Products.

• Over the Counter Medication.

• Research & Development.

MAJOR THERAPEUTIC AREAS

7 major therapeutic areas- Cardiovascular Central Nervous System Diabetes Internal Medicine Oncology Thrombosis Vaccines (World’s largest producer)

POSITIONING OF DIABETES MEDICINE

• Apidra and Lantus are main products.• APIDRA-

-Rapid-acting. -Works fast.-Used in children 4 years and

older with type 1 diabetes.-Adults with type 1 or type 2 diabetes.

POSITIONING

LANTUS• Adult and pediatric patients with type 1 diabetes mellitus .

• Adult patients with type 2 diabetes mellitus

TOP PHARMACEUTICAL COMPANIES WITH REVENUES AS PER 2009 ANNUAL REPORT

1. Johnson & Johnson (U.S.) - $ 6,1902. Pfizer (U.S.) - $ 5,0013. Roche (Switzerland) - $4,7354. Glaxo Smith Kline (U.K.) - $4,5835. Novartis (Switzerland) - $4,4276. Sanofi Aventis (France) - $4,199

MARKET SHARE OF DIFFERENT COMPANIES

MAJOR COMPETITORS IN U.S.A.

• Johnson & Johnson

• Pfizer

• Glaxo Smith Kline

• Bristol-Myers Squibb

• Astra Zeneca

BRISTOL-MYERS SQUIBB

• Founded in - 1989

• Revenue - $18.8 billion(2009)

• Operating Income - $5.34 billion(2009)

• Employee’s - 28,000 (2009)

MAIN PRODUCTIONS AREAS INCLUDE

• Cancer• HIV/AIDS • Cardiovascular disease • Diabetes• Hepatitis • Rheumatoid Arthritis & • Psychiatric disorders.

DISTRIBUTION ALL OVER THE WORLD

POSITIONING OF MEDICINE FOR DIABETES

• ONGLYZA™ (saxagliptin) is the main product for diabetes.

• Developed and marketed through a collaboration with AstraZeneca.• For the treatment of type 2 diabetes in adults.

JOHNSON & JOHNSON



• Operating Income - $15.7 billion(2009)

• Employee’s - 118,700 (2009)


• Medical devices• Health care products • Toiletries • Soaps • Shampoos


• CANAGLIFLOZIN is the main Product.

• For Oral Type 2 diabetes.

• Promote Weight Loss in Treatment of Type 2 Diabetes.

PFIZER



• Net Income - $8.63 billion(2009)

• Employee’s - 116,500 (2009)

• Ranked No. 2 in sales


• Lipitor( to lower blood cholesterol)

• Lyrica (neuropathic drug)

• Diflucan (the oral antifungal)

• Antibiotic Zithromax.


• EXUBERA for diabetes and Insulin Therapies

• Exubera is an Inhaled Insulin for Type 1 and Type 2 Diabetes• Many drugs can interfere with Exubera.

GLAXO SMITH KLINE


• Revenue - £28.36billion(2009)

• Net Income - £5.66 billion (2009)

• Employee’s - 99,000 (2009)

• Ranked No. 1 in sales


• Asthma • Cancer • Virus control • Mental health • Diabetes and • Digestive conditions


• AVANDIA is the main product for diabetes.• Oral Drug.• To treat Type-2 diabetes.• Increase the risk of Heart attack, Strokes, Fractures, Eye damage.

ASTRA ZENECA


• Revenue -$32,804 million(2009)

• Net Income - $7,544 million(2009)

• Employee’s - 116,500 (2009)


• Cancer • Cardiovascular • Gastrointestinal infection • Neuroscience • Respiratory disorder • Inflammation.• THEY HAVE NO PRODUCT FOR DIABETES.

MAJOR COMPETITORS IN BRAZIL

• Atlanta Pharmaceuticals.

• Bayer’s Pharmaceuticals.

• Novartis Pharmaceuticals.

• Roche Pharmaceuticals.

• Ache Laboratories Pharmaceuticals.

BAYER’S PHARMACEUTICALS


• Revenue - €31.17billion(2009)

• Net Income - €3.0 billion (2009)

• Employee’s - 108,400 (2009)


• Veterinary drugs

• General and specialty medicines

• Women's health products

• Over-the-counter drugs

• Diabetes care

PRODUCT FOR DIABETES

• Bayer’s Contour USB Meter for measuring Blood Glucose.

• Bayer’s Entrust for measuring Blood Glucose.

NOVARTIS PHARMACEUTICALS


• Revenue - $44.27billion(2009)

• Net Income - $8.40 billion (2009)

• Employee’s - 99,830


• Pharmaceuticals

• Generic drugs

• Over-the-counter drugs

• Vaccines

• Contact lenses

POSITIONING FOR DIABETES

• Novartis resource Diabetishield

• A Nutritional drink formulated for Individuals with Diabetes.

• Added arginine, chromium, and vitamins C and E help to improve insulin sensitivity and aid in blood sugar control.

ROCHE PHARMACEUTICALS


• Revenue - CHF 49.05billion(2009)

• Net Income - CHF 12.28 billion (2009)

• Employee’s - 81,500 (2009)


• PharmaceuticalsXenical(Obesity) Zenapax(Monoclonal Antibody) Valcyte(Antiviral) Bactrim (Antibiotic)Tamiflu (Antiviral)

• Diagnostics


• Accu-Chek is the brand of blood sugar -testing device. Include-

• Accu-Chek Aviva • Accu-Chek • Compact Plus

ACHE LABORATORIES PHARMACEUTICALS


• The best pharmaceutical lab in Brazil.


MISSION, VISION AND VALUES

• VISION- Be the best pharmaceutical lab in Brazil. Preferred by consumers and health

professionals. Promote the health and well-being of

the entire population.

MISSION

Continuously make available with quality.Creativity and convenience.Innovative and accessible products and

services that promote consumer health and well being.

Respect to people and the environment.

VALUES

IntegrityRespect to PeopleRespect to the EnvironmentEnterprising SpiritInnovationSustainable Growth

COMPETITORS IN GERMANY

• Boehringer Ingelheim

• Merck KGaA

• Generics

• Phytomedicines

• Bayer Schering Pharma

BOEHRINGER INGELHEIM


• Revenue - €11.595 billion (2008)

• Net Income - €1.424 billion (2008)

• Employee’s - 41,300 (2008)

MAIN PRODUCTION AREAS

• Human Pharmaceuticals Prescription medicines Healthcare products

• Biopharmaceuticals • Chemicals• Animal health products


• LINAGLIPTIN is the main product.

• Effective against Type-II Diabetes.

• Oral Medicine.

• Still under trial.

MERCK KGAA



• Operative Income - €620.9 million (2009)

• Employee’s - 40,507 (2010)


• Liquid crystals• Life science and performance chemicals• Over-the-counter medicines• Small molecules • Biopharmaceuticals


• JANUVIA is drug which works for the management of Type 2 diabetes.• Oral Medicine.• Side Effects- severe pain in stomach nausea and vomiting, loss of appetite, fast heart rate, fever, sore throat.

BAYER SCHERING PHARMA



• Employee’s - 26,000 (2004)

• Headquarter - Germany


• Gynaecology & Andrology• Special therapeutics Diagnostical devices• Nuclear medicine• Oncology


• Launched SciLin a recombinant insulin product, in China.

• Oral Drug for Adults.

COMPETITORS IN INDIA

• Ranbaxy (Daiichi)

• Dr. Reddy’s Laboratories

• Cipla

• Sun Pharma

• Aurobindo Pharma

RANBAXY (DAIICHI)


• Revenue - US$ 1,405 million (2010)

• Net Income - US$ 349 million (2010)

• Employee’s - 1,100 in R & D

• Operating in over - 125 Countries

• Market Share in India - 4.9%

MAIN PRODUCTION AREAS• Cardiovascular• Central Nervous System• Respiratory• Dermatology• Orthopedics• Nutritionals • Urology


• VOLIX (VOGLIBOSE) is the main product for Treatment Of Diabetes.

• Help in improving of Postprandial Hyperglycemia in Diabetes Mellitus.

• Oral Drug.• Will Launch anti-diabetic drug ACTOS in the US by 2012.

Dr. REDDY’S LABORATORIES


• Revenue - US$ 1.5 billion (2007)

• Net Income - US$ 216 million (2007)


• Major seller in Europe, Canada and Russian.

• Number one in India in terms of profitability.


• Cancer

• Diabetes

• Cardiovascular disease

• Inflammation

• Bacterial infection


• BALAGLITAZONE is the main product for Diabetes.• First lead molecule in anti-diabetic segment.• RAGAGLITAZONE is a new product & is more

promising.

CIPLA


• Revenue - US$ 1.28 billion (2010)

• Net Income - US$ 245.7 million (2010)


• 2nd Largest Pharmaceutical Company in India in terms of retail sales.

Operating in 170 Countries.


• Pharmaceuticals• Animal Health Care Products• OTC (Over The Counter) Drug• Bulk Drugs• Flavours & Fragrances• Agrochemicals


• ACARBOSE is main product used for type 2 diabetes mellitus.

• Oral Medicine.• Side Effects- Diarrhea, Hypoglycemia, Dizziness, Headache.

SUN PHARMA


• Revenue - Rs 42.7 billion (2009)

• Net Income - Rs 18.7 billion (2009)

• Employee’s - 8,000 (2008)


• Anticancer• Analgesics• Antidepressant• Antidiabetic• Antihypertensive• Cardiovascular


• GLIMEPRIDE & METFORMINE are the main drugs.

• Used for Type 2 Diabetes.• Oral Medicine for Adults.

COMPETITOR’S IN AUSTRALIA

• Novogen

• Amrad Corporation

• Biota Holdings Ltd.

• Novo Nordisk

• Pfizer Australia

COMPETITOR’S IN JAPAN

• Daiichi Sankyo Co.

• Astellas

• Chugai Pharma

• Eisai Co.

• Takeda Pharma

DAIICHI SANKYO COMPANY


• Revenue - ¥ 880,120 million (2007)

• Net Income - ¥ 97,660 million (2007)

• Employee’s - 15,349 (2008)

DIFFERENT PRODUCTS

• Cravit

• Evoxac

• FloxinOtic

• Gracevit

• Rivoglitazone—Type 2 Diabetes. It is still under trial.

EISAI COMPANY


• Revenue - ¥ 781.7 billion (2008)

• Net Income - ¥ 47.7 billion (2008)

• Employee’s - 10,962 (2008)

DIFFERENT PRODUCTS

• Aciphex/Pariet (Gastroesophageal reflux disease)• Actonel (Osteoporosis)• Methylcobal (Peripheral Neuropathy)• Myonal (Muscle relaxant)• AS-3201 (Diabetic neuropathy)

ASTELLAS PHARMA


• Revenue - ¥ 972.6 billion (2007)

• Net Income - ¥ 177.4 billion (2007)

• Employee’s - 13,900 (2007)

DIFFERENT PRODUCTS

• Prograf (Prevention of post- transplant organ rejection)

• Protopic (Atopic dermatitis)

• AmBisome (Anti-fungal)

• Mycamine (Anti-fungal)

THANK YOU

AMARJIT SINGH

Mm II Assignment

Health & Medicine

Transcript of Mm II Assignment